Jochen B. Fiebach

Jochen B. Fiebach

Auto-generated profile, based on publicly available information

Jochen B. Fiebach

Centre for Stroke Research Berlin, Charité Universitätsmedizin Berlin, Berlin, Germany

Research Focus & Metrics

Academic Career Length

28Years (1999-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 November 2011 in The Lancet Neurology
Verified
Journal Article
Closed access
GTGötz Thomalla
Götz Thomalla
BCBastian Cheng
Bastian Cheng
MEMartin Ebinger
Martin Ebinger
QHQing Hao
Qing Hao
TTThomas Tourdias
Thomas Tourdias
CGChristian Gerloff
Christian Gerloff

1 February 2009 in The Lancet Neurology
Verified
Journal Article
Closed access
WHWerner Hacke
Werner Hacke
AFAnthony J Furlan
Anthony J Furlan
YAYasir Al-Rawi
Yasir Al-Rawi
ADAntoni Davalos
Antoni Davalos
JFJochen B Fiebach
Jochen B Fiebach
SWSteven Warach
Steven Warach

1 September 2002 in Stroke
Verified
Journal Article
Closed access
PDF file
JFJ.B. Fiebach
J.B. Fiebach
PSP.D. Schellinger
P.D. Schellinger
OJO. Jansen
O. Jansen
MMM. Meyer
M. Meyer
PWP. Wilde
P. Wilde
KSK. Sartor
K. Sartor
Background and Purpose— Diffusion-weighted MRI (DWI) has become a commonly used imaging modality in stroke centers. The value of this method as a routine procedure is still being discussed. In previous studies, CT was always performed before DWI. Therefore, infarct progression could be a reason for the better result in DWI. Methods— All hyperacute (3 were prospectively randomized for the order in which CT and MRI were performed. Five stroke experts and 4 residents blinded to clinical data judged stroke signs and lesion size on the images. To determine the interrater variability, we calculated κ values for both rating groups. Results— A total of 50 patients with ischemic stroke and 4 patients with transient symptoms of acute stroke (median NIHSS score, 11; range, 3 to 27) were analyzed. Of the 50 patients, 55% were examined with DWI first. The mean delay from symptom onset until CT was 180 minutes; that from symptom onset until DWI was 189 minutes. The mean delay between DWI and CT was 30 minutes. The sensitivity of infarct detection by the experts was significantly better when based on DWI (CT/DWI, 61/91%). Accuracy was 91% when based on DWI (CT, 61%). Interrater variability of lesion detection was also significantly better for DWI (CT/DWI, κ=0.51/0.84). The assessment of lesion extent was less homogeneous on CT (CT/DWI, κ=0.38/0.62). The differences between the 2 modalities were stronger in the residents’ ratings (CT/DWI: sensitivity, 46/81%; κ=0.38/0.76). Conclusions— CT and DWI performed with the same delay after onset of ischemic stroke resulted in significant differences in diagnostic accuracy. DWI gives good interrater homogeneity and has a substantially better sensitivity and accuracy than CT even if the raters have limited experience.

23 April 2014 in JAMA
Verified
Journal Article
Open access
PDF file
MEMartin Ebinger
Martin Ebinger
BWBenjamin Winter
Benjamin Winter
MWMatthias Wendt
Matthias Wendt
JWJoachim E. Weber
Joachim E. Weber
CWCarolin Waldschmidt
Carolin Waldschmidt
HAHeinrich J. Audebert
Heinrich J. Audebert
Stroke is a leading cause of death and disability.1 In acute ischemic stroke, thrombolysis with intravenous tissue plasminogen activator (tPA) is the treatment of choice after exclusion of intracerebral hemorrhage by brain imaging.2 Neurons die rapidly during ischemia, and randomized placebo-controlled trials have shown time-dependent benefits of tPA: early treatment is associated with better outcomes.3-7 Within 90 minutes of symptom onset, the number needed to treat for 1 excellent outcome is 4.5; the number is 9 between 91 and 180 minutes and 14 between 181 and 270 minutes.5 However, only a minority of stroke patients receive tPA,8 and in a European stroke registry only 11% of this minority were treated within the first 90 minutes.9 Apart from delayed patient response, prehospital and intrahospital management (“onset-to-door” and “door-to-needle”) contribute to delays. Onset-to-door times range from 46 to 150 minutes,10 and recent data from the United States indicate that less than 30% of patients have a door-to-needle time within the recommended 60 minutes.2,8 Recently, one study reported time saving in 12 tPA administrations performed in a special ambulance with integrated computed tomography (CT) scanner and point-of-care laboratory.11 Little is known about the overall effects and risks of specialized ambulances for patients with stroke and also for patients with other diseases. After a 3-month pilot study with the Stroke Emergency Mobile (STEMO),12 we investigated the effects of its deployment on time to treatment and safety in a larger controlled study.13

1 February 2004 in Stroke
Verified
Journal Article
Closed access
JFJochen B. Fiebach
Jochen B. Fiebach
PSPeter D. Schellinger
Peter D. Schellinger
AGAchim Gass
Achim Gass
TKThomas Kucinski
Thomas Kucinski
MSMario Siebler
Mario Siebler
KSKlaus Sartor
Klaus Sartor
Background and Purpose— Although modern multisequence stroke MRI protocols are an emerging imaging routine for the diagnostic assessment of acute ischemic stroke, their sensitivity for intracerebral hemorrhage (ICH), the most important differential diagnosis, is still a matter of debate. We hypothesized that stroke MRI is accurate in the detection of ICH. To evaluate our hypotheses, we conducted a prospective multicenter trial. Methods— Stroke MRI protocols of 6 university hospitals were standardized. Images from 62 ICH patients and 62 nonhemorrhagic stroke patients, all imaged within the first 6 hours after symptom onset (mean, 3 hours 18 minutes), were analyzed. For diagnosis of hemorrhage, CT served as the “gold standard.” Three readers experienced in stroke imaging and 3 final-year medical students, unaware of clinical details, separately evaluated sets of diffusion-, T2-, and T2*-weighted images. The extent and phenomenology of the hemorrhage on MRI were assessed separately. Results— Mean patient age was 65.5 years; median National Institutes of Health Stroke Scale score was 10. The experienced readers identified ICH with 100% sensitivity (confidence interval, 97.1 to 100) and 100% overall accuracy. Mean ICH size was 17.3 mL (range, 1 to 101.5 mL). The students reached a mean sensitivity of 95.16% (confidence interval, 90.32 to 98.39). Conclusions— Hyperacute ICH causes a characteristic imaging pattern on stroke MRI and is detectable with excellent accuracy. Even raters with limited film-reading experience reached good accuracy. Stroke MRI alone can rule out ICH and demonstrate the underlying pathology in hyperacute stroke.

12 May 2016 in Alzheimer's Research & Therapy
Verified
Journal Article
Open access
PDF file
RVRik Vandenberghe
Rik Vandenberghe
JRJuha Rinne
Juha Rinne
MBMerce Boada
Merce Boada
SKSadao Katayama
Sadao Katayama
PSPhilip Scheltens
Philip Scheltens
RBRonald S. Black
Ronald S. Black
Background: Our objective was to evaluate the efficacy (clinical and biomarker) and safety of intravenous bapineuzumab in patients with mild to moderate Alzheimer’s disease (AD). Methods: Two of four phase 3, multicenter, randomized, double-blind, placebo-controlled, 18-month trials were conducted globally: one in apolipoprotein E ε4 carriers and another in noncarriers. Patients received bapineuzumab 0.5 mg/kg (both trials) or 1.0 mg/kg (noncarrier trial) or placebo every 13 weeks. Coprimary endpoints were change from baseline to week 78 on the 11-item Alzheimer’s Disease Assessment Scale–Cognitive subscale and the Disability Assessment for Dementia. Results: A total of 683 and 329 patients completed the current carrier and noncarrier trials, respectively, which were terminated prematurely owing to lack of efficacy in the two other phase 3 trials of bapineuzumab in AD. The current trials showed no significant difference between bapineuzumab and placebo for the coprimary endpoints and no effect of bapineuzumab on amyloid load or cerebrospinal fluid phosphorylated tau. (Both measures were stable over time in the placebo group.) Amyloid-related imaging abnormalities with edema or effusion were confirmed as the most notable adverse event. Conclusions: These phase 3 global trials confirmed lack of efficacy of bapineuzumab at tested doses on clinical endpoints in patients with mild to moderate AD. Some differences in the biomarker results were seen compared with the other phase 3 bapineuzumab trials. No unexpected adverse events were observed. Trial registration: Noncarriers (3000) ClinicalTrials.gov identifier NCT00667810; registered 24 Apr 2008. Carriers (3001) ClinicalTrials.gov identifier NCT00676143; registered 2 May 2008.